Cephamycins, a new family of beta-lactam antibiotics. IV. In vivo studies.
Cephamycin A was found to be more active in vivo than cephamycin B. In comparison with cephamycin C, cephamycin A was more active against gram-positive organisms but less active against gram-negative organisms. Given subcutaneously, cephamycin C had good in vivo gram-negative activity, comparing favorably with cephalothin and cephaloridine against cephalosporin-susceptible organisms. In general, against the gram-negative organisms, it was more active than cephalothin or cephalosporin C and about as active as cephaloridine. In addition, cephamycin C protected mice against beta-lactamase-producing Proteus cultures, including clinically isolated strains. The compound is remarkably nontoxic. Cephamycin C was detected in the serum and recovered from the urine of treated mice to about the same extent as cephaloridine. Like cephaloridine and cephalosporin C, cephamycin C must be excreted mainly by glomerular filtration, because the use of probenecid did not enhance the therapeutic effectiveness nor concentrations of these agents in the sera of treated mice.
D000818:Animals; D001424:Bacterial Infections / Q000517:prevention & control*; D002511:Cephalosporins / Q000378:metabolism / Q000627:therapeutic use* / Q000633:toxicity; D005260:Female; D051379:Mice; D011339:Probenecid / Q000494:pharmacology / Q000627:therapeutic use
D002511:Cephalosporins; D011339:Probenecid